Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Casi Phrmactcls Inc (CASI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 496,161
  • Shares Outstanding, K 86,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,770 K
  • 36-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.07
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.57 +1.49%
on 09/19/18
8.20 -31.13%
on 08/21/18
-2.37 (-29.58%)
since 08/20/18
3-Month
5.16 +9.45%
on 06/22/18
8.89 -36.47%
on 08/13/18
-0.05 (-0.92%)
since 06/20/18
52-Week
1.69 +234.18%
on 10/04/17
8.89 -36.47%
on 08/13/18
+3.84 (+212.03%)
since 09/20/17

Most Recent Stories

More News
CASI Pharmaceuticals Announces $48.5 Million Private Placement

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 5.67 (-1.05%)
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 5.67 (-1.05%)
CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 5.67 (-1.05%)
Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cabot Oil & Gas Corporation...

AA : 43.39 (+1.78%)
BTU : 41.52 (-3.73%)
EW : 151.46 (+1.84%)
COG : 22.86 (+2.70%)
CASI : 5.67 (-1.05%)
CHSP : 33.15 (+0.09%)
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 5.67 (-1.05%)
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc....

ETP : 22.39 (+0.18%)
KALV : 17.91 (+10.15%)
IRWD : 17.15 (+0.29%)
CY : 16.05 (+2.16%)
CASI : 5.67 (-1.05%)
XEL : 47.19 (+0.15%)
New Report Released on Growing Biotech Sector

FN Media Group Presents Microcapspeculators.com News Commentary

DRNA : 16.43 (+0.67%)
PPCHD : 1.2000 (+20.00%)
IONS : 50.95 (+1.94%)
PPCB : 0.0625 (+3.14%)
CASI : 5.67 (-1.05%)
INSM : 21.23 (+4.53%)
CASI Pharmaceuticals Provides Update On EVOMELA®

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 5.67 (-1.05%)
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 5.67 (-1.05%)
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, today...

CASI : 5.67 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CASI with:

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

2nd Resistance Point 6.20
1st Resistance Point 5.97
Last Price 5.67
1st Support Level 5.53
2nd Support Level 5.33

See More

52-Week High 8.89
Fibonacci 61.8% 6.14
Last Price 5.67
Fibonacci 50% 5.29
Fibonacci 38.2% 4.44
52-Week Low 1.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar